U.S. FDA Approves First Therapeutic Indication for Revance's DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

- Provides Revance entry into the $2.5 billion U.S. therapeutic neuromodulator market.1


- Approval expands the DAXXIFY® label to include efficacy data over the 52-week ASPEN repeat dose clinical...
-Today at 08:04 am- MarketScreener

Related Keywords

China ,United States ,American ,Americans ,Markj Foley ,Peter Mcallister ,Association Of Academic Physiatrists Annual Meeting ,Peptide Exchange Technology ,Revance Therapeutics Inc ,American Academy Of Physical Medicine ,Securities Exchange ,Nasdaq ,Dystonia Medical Research Foundation ,Drug Administration ,Exchange Commission ,England Institute For Neurology ,Hint Inc ,Viatris Inc ,Linkedin ,Revance Therapeutics ,Chief Executive Officer Mark ,New England Institute ,Label Study ,Boxed Warning ,Distant Spread ,Specific Populations ,Prescribing Information ,Relational Commerce ,Shanghai Fosun Pharmaceutical ,Resilient Hyaluronic Acid ,Private Securities Litigation Reform Act ,Securities Act ,Securities Exchange Act ,Cervical Dystonia ,Medical Research ,Injection Through Multiple Cycles ,Multicenter Trial ,American Academy ,Physical Medicine ,Rehabilitation Annual Meeting ,Injection Over Successive Treatments ,Adults With Isolated Cervical Dystonia ,Academic Physiatrists Annual Meeting ,Markets ,